First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial.
Wang ZX, Peng J, Liang X, Cheng Y, Deng Y, Chen K, Zhang M, Zhang J, Wang W, Cao B, Jin Y, Sun M, Lin Y, Luo S, Li Z, Yang L, Ke Y, Yu H, Li J, Wang Q, Zhu J, Wang F, Xu RH.
Wang ZX, et al. Among authors: sun m.
Med. 2024 Jun 9:S2666-6340(24)00213-7. doi: 10.1016/j.medj.2024.05.009. Online ahead of print.
Med. 2024.
PMID: 38870931